biogen idec

Here's a quick look at nine of the best-performing biotech stocks of the past year. Achillion Pharmaceuticals (NASDAQ: ACHN) is up almost 88% year to date and about 37% higher just in the past month. This Connecticut-based biopharmaceutical company has three drugs in clinical trials to treat...

While the markets were down yesterday, news that Gilead Sciences (NASDAQ: GILD) would acquire Pharmasset (NASDAQ: VRUS) pushed some biotech stocks higher. Idenix Pharmaceuticals (NASDAQ: IDIX) and Spectrum Pharmaceuticals (NASDAQ: SPPI) reached new multiyear highs of $8.05 and $13.00 per share,...

The earnings crunch is in full swing this this week. Quarterly results are due from the likes of Caterpillar (NYSE: CAT), Exxon Mobil (NYSE: XOM), Procter & Gamble (NYSE: PG) and United Parcel Service (NYSE: UPS), from which analysts expect to see year-over-year earnings growth, as well as...

Citadel Securities has published a report on Biogen Idec Inc (NASDAQ: BIIB) intiating coverage on the biotech company. In the report, Citadel Securities wrote, "Biogen's hemophilia pipeline may provide an additional high-margin growth driver, in our view, although we await final data expected in...

iShares Dow Jones US Healthcare Provider (NYSE: IHF) is up more than 19% year to date. The fund invests at least 90% of its assets in securities of the underlying index, which measures the performance of the health care providers sector of the U.S. equity market. Top holdings include UnitedHealth...

PowerShares S&P SmallCap Health Care (NYSE: PSCH) is up nearly 22% year to date. The investment seeks to replicate the S&P SmallCap 600 Capped Health Care index, which is comprised of common stocks of U.S. health care companies. Top holdings include Regeneron Pharmaceuticals (NASDAQ: REGN...

Deutsche Bank is out with its report today on Biogen Idec (NASDAQ: BIIB), upgrading BIIB from Hold to Buy. In a note to clients, Deutsche Bank writes, "We view Biogen Idec as the large cap biotech stock with the greatest opportunity for upside: 1) Our analysis suggests CONFIRM will show BG-12 is...

Deutsche Bank made a number of updates in a research report published today. Biogen Idec (NASDAQ: BIIB) had its rating upgraded from Hold to Buy. At the same time, Deutsche Bank raised its price target on the company's stock from $106 to $129. In the report, Deutsche Bank states, "Upgrading to...

Deutsche Bank has raised the price target on Biogen Idec (NASDAQ: BIIB) from $106 to $129 and has upgraded the company from Hold to Buy.

ISI Group has upgraded Biogen (NASDAQ: BIIB) to Buy.

Shares of Micromet (NASDAQ: MITI), a biopharmaceutical company based in Rockville, Maryland, closed up 8.7% Friday. In a press release, the company said research suggests that its new antibody agent called blinatumomab, may be a useful weapon against acute lymphoblastic leukemia (ALL)....

Jefferies reiterated its Buy rating on Biogen Idec (NASDAQ: BIIB) after a meeting with a leading multiple sclerosis expert. In a research report published today, Jefferies stressed that the expert believes some of Biogen's products will perform very well. In the report, Jefferies states, "We had...

“The outperformance has largely been led by the SMIDs, which in our coverage are up 45% YTD vs. 11% for large caps (and 4% excluding outlier Biogen Idec Inc. (NASDAQ: BIIB)), where the new product story has increasingly become better and has the potential to drive sustainable growth bringing...

Jefferies & Company has raised the price target on Biogen Idec (NASDAQ: BIIB) from $100 to $120 and maintains its Buy rating.

Citi is out with its report today on Biogen Idec (NASDAQ: BIIB), maintaining High Risk. In a note to clients, Citi writes, "We rate the shares of Biogen Idec High Risk given Tysabri PML risks, competitive threats and strategic challenges that the company faces." Shares of BIIB closed Monday at $...